Favezelimab

DB16729InvestigationalProtein Based Therapies

Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).

Mechanism: Pharmacologically active on Lymphocyte activation gene 3 protein
Curator reviewed
Also known as: Mavezelimab
Code names: MK-4280

Resolves to

Compound

UNIIH1396W7D1HCAS2231068-83-8

Targets

P18627LAG3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Favezelimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account